YunYenMD

Oncology • Duarte, CA

Academic practice

Join to view full profile

Dr. Yen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Yen's full profile

Already have an account?

Office
1500 E Duarte Rd
Duarte, CA 91010
Phone+1 626-359-8111
Is this information wrong?

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1991 - 1993
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1991
St Luke's University HospitalResidency, Internal Medicine, 1987 - 1990
Taipei Medical UniversityClass of 1982

Certifications & Licensure

CA State Medical License 1989 - 2024
CT State Medical License 1990 - 1993

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2006-2014
Top Doctors:LA Area Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Top Doctors:Southern California Castle Connolly, 2012
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Oxaliplatin in Treating Patients With Liver Cancer Start of enrollment: 2002 Sep 01
Completed
Phase 2
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors Start of enrollment: 2006 May 01
Completed
Phase 1, Phase 2
3-AP in Treating Patients With Advanced or Metastatic Solid Tumors Start of enrollment: 2006 Dec 01
Completed
Phase 1
High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer Start of enrollment: 2006 Apr 01
Completed
Phase 1
Safety Study of CALAA-01 to Treat Solid Tumor Cancers Start of enrollment: 2008 May 01
Terminated
Phase 1
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer Start of enrollment: 2014 Jun 11
Completed
Phase 1
A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer Start of enrollment: 2006 Nov 01
Terminated
Phase 2
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) Start of enrollment: 2020 Jan 10
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

6 citations
Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies.
Chieh Yang, John Nguyen, Yun Yen
Journal of Biomedical Science. 2023-10-21
9 citations
Primary Cutaneous Anaplastic Large Cell Lymphoma With Positive ALK Expression and a Rapidly Progressive Cutaneous Nodule
Dan Xue, Xiuzhen Li, Yunqing Ren, Qi Liu, Yun Yen
International Journal of Surgical Pathology. 2015-01-29
77 citations
Amplification of FRS2 and Activation of FGFR/FRS2 Signaling Pathway in High-Grade Liposarcoma
Keqiang Zhang, Kevin C. Chu, Xiwei Wu, Hanlin Gao, Jinhui Wang
Cancer Research. 2013-02-15

Press Mentions

Tang Prize Laureates Reflect on the Breakthroughs Made Possible by Cytokine ResearchNovember 27th, 2021

Other Languages

Chinese (Mandarin)